Davidov M I, Mitiagin P N, Maksiutova A S
Urologiia. 2009 Nov-Dec(6):11-7.
Efficacy and tolerance of furamag and norbactin were compared in a prospective controlled trial with participation of 82 females aged 18-60 years with acute uncomplicated cystitis. All the women were divided into two groups. Group 1 (n=42) received norbactin (norfloxacin) in a dose 400 mg twice a day for 7 days. Group 2 (n=40) was given furamag in a dose 50 mg 3 times a day for 10 days. The results were evaluated 2 weeks after the treatment. The comparison of the treatment results showed that a new nitrofuranic drug furamag has significantly higher clinical and bacteriological efficacy: acute cystitis was cured in 95% patients, eradication of the infective agent occurred in 96.4% patients, tolerance was good in 97.5% patients. Sensitivity of the agents causing acute cystitis to nitrofurans reached 98.2% while to norbactin--only 86%.
在一项前瞻性对照试验中，对82名年龄在18至60岁的患有急性单纯性膀胱炎的女性进行了呋喃马哥（furamag）和诺邦菌素（norbactin）的疗效及耐受性比较。所有女性被分为两组。第1组（n = 42）接受诺邦菌素（诺氟沙星），剂量为400毫克，每日两次，共7天。第2组（n = 40）服用呋喃马哥，剂量为50毫克，每日三次，共10天。治疗后2周评估结果。治疗结果比较显示，新型硝基呋喃类药物呋喃马哥具有显著更高的临床和细菌学疗效：95%的患者急性膀胱炎得到治愈，96.4%的患者感染病原体被根除，97.5%的患者耐受性良好。引起急性膀胱炎的病原体对硝基呋喃类药物的敏感性达到98.2%，而对诺邦菌素仅为86%。
